Cargando…

Differences in Fatty Acid Oxidation between Nab-Paclitaxel- and Solvent-Based Paclitaxel-Treated A549 Cells Based on Metabolomics

[Image: see text] The pharmacokinetics, safety, and anticancer efficacy profiles of nanoparticle albumin-bound (nab)-paclitaxel formulations are superior to those of solvent-based paclitaxel formulations. The aims of the present study were to study the effects of nab-paclitaxel and solvent-based pac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Jhih-Wei, Kuo, Ching-Hua, Kuo, Han-Chun, Shih, Jin-Yuan, Tsai, Teng-Wen, Chang, Lin-Chau
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931197/ https://www.ncbi.nlm.nih.gov/pubmed/33681555 http://dx.doi.org/10.1021/acsomega.0c04385

Ejemplares similares

Cell metabolomics analyses revealed a role of altered fatty acid oxidation in neurotoxicity pattern difference between nab-paclitaxel and solvent-based paclitaxel
por: Huang, Jhih-Wei, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent-based paclitaxel
por: Chen, Nianhang, et al.
Publicado: (2014)

Solvent-based paclitaxel or nab-paclitaxel for heavily treated relapsed/refractory small cell lung cancer: Retrospective single-institution observational study
por: Sugiyama, Keiji, et al.
Publicado: (2019)

Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel()
por: de Leon, Maria C.B., et al.
Publicado: (2013)

nab-Paclitaxel for the treatment of pancreatic cancer
por: Kim, George
Publicado: (2017)

Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
por: Kokubu, Hiraku, et al.
Publicado: (2023)

Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective
por: Dranitsaris, George, et al.
Publicado: (2015)

Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer
por: Wan, Rui, et al.
Publicado: (2023)

nab-Paclitaxel dose and schedule in breast cancer
por: Martín, Miguel
Publicado: (2015)

Neoadjuvant nab-paclitaxel in the treatment of breast cancer
por: Ueno, Naoto T., et al.
Publicado: (2016)

nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma
por: Makimoto, Go, et al.
Publicado: (2014)

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab−Paclitaxel and Maintenance Monotherapy with nab−Paclitaxel: Two Case Reports
por: Araya, Tomoyuki, et al.
Publicado: (2020)

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report
por: Funaishi, Kunihiko, et al.
Publicado: (2017)

Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration
por: Chen, Nianhang, et al.
Publicado: (2015)

Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer
por: Al-Hajeili, Marwan, et al.
Publicado: (2014)

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
por: Alvarez, R, et al.
Publicado: (2013)

A Case of Stress Cardiomyopathy With Nab-Paclitaxel Infusion
por: Singh, Harjinder, et al.
Publicado: (2023)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
por: Zong, Yuan, et al.
Publicado: (2020)

Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis
por: Liu, Miao, et al.
Publicado: (2021)

Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer
por: Rajeshkumar, N V, et al.
Publicado: (2016)

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study
por: Lazzaro, Carlo, et al.
Publicado: (2013)

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
por: Chen, Shuling, et al.
Publicado: (2023)

The Anti-Tumor Effect of Nab-Paclitaxel Proven by Patient-Derived Organoids
por: Xiao, Xing, et al.
Publicado: (2020)

Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval
por: Yamamoto, Yutaka, et al.
Publicado: (2011)

Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer
por: Vishnu, Prakash, et al.
Publicado: (2011)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014)

Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer
por: De Luca, Rossella, et al.
Publicado: (2018)

Nab-paclitaxel - Third-line chemotherapy in advanced gallbladder cancer
por: Patel, Amol, et al.
Publicado: (2020)

Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma
por: Yang, Yafan, et al.
Publicado: (2023)

Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer Patients
por: Borgå, Olof, et al.
Publicado: (2019)

Toxicity of Nab-Paclitaxel Compared to Paclitaxel in a Tertiary Hospital in Jeddah, Saudi Arabia: A Retrospective Cohort Study
por: Alhebshi, Suha A, et al.
Publicado: (2023)

Reply: ‘Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'
por: Alvarez, R, et al.
Publicado: (2014)

Erratum: Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
Publicado: (2014)

nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
por: Soliman, Hatem H
Publicado: (2016)

nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings
por: Brufsky, Adam
Publicado: (2017)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
por: Comandatore, Annalisa, et al.
Publicado: (2022)

Clinical Characteristics and Risk Factors of Lung Injury Induced by Nab-Paclitaxel
por: Yoshioka, Keiichiro, et al.
Publicado: (2022)

Study on the thermal stability of nab-paclitaxel during hyperthermic intraperitoneal chemotherapy
por: Zhang, Jingjing, et al.
Publicado: (2023)

Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
por: Hassan, Md Sazzad, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_63mtqu5kf7solisf2suj13bak2